Sun Pharma denies $12B Organon deal rumour, calls news speculative

Sun Pharmaceutical Industries Ltd. has responded to a news item published on moneycontrol.com regarding a potential $12 billion deal with Organon, which reportedly caused its stock to slip. The company clarified that the information in the article is speculative in nature. Sun Pharma stated that there is no material event or information that requires disclosure under Regulation 30 of the Listing Regulations. The company reaffirmed its commitment to the highest standards of governance and disclosures, promising to keep stock exchanges informed of any material events as required.